RXRX RECURSION PHARMACEUTICALS, INC.

CIK 0001601830 37 ready 8-Ks latest May 6, 2026, 7:59 PM ET RSS · JSON

Ready 8-Ks 37

Latest filing May 6, 2026, 7:59 PM ET

Top materiality 0.85

Event mix other_material ×13 · m_and_a ×8 · earnings ×6

Sentiment 13 pos · 1 neg · 23 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for RXRX

Highest-materiality recent filing

Recursion completes Exscientia acquisition; issues 102M shares, names new CFO

November 20, 2024, 6:59 PM ET M&A materiality 0.85 neutral item 2.01 item 5.02 item 7.01 item 8.01 item 9.01 item 6.01

Acquisition of Exscientia effective Nov 20, 2024 via UK scheme; 0.7729 Recursion shares per Exscientia share; 102,138,419 shares issued.
Exscientia ADSs (EXAI) delisted from Nasdaq; equity awards converted to Recursion options/RSUs using Exchange Ratio.

Read filing →

May 6, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01

Recursion Q1 net loss narrows to $117.5M; REC-1245 safety data positive, REC-4539 dosed

Net loss of $117.5M vs $202.5M YoY; revenue $6.5M, down 56% YoY on lower Roche milestone phasing.
February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Recursion Q4 revenue $35.5M; first AI-driven clinical validation in FAP; cash runway to 2028

Q4 revenue $35.5M (up from $4.5M YoY); net loss $108.1M vs $178.9M; cash $753.9M.
December 8, 2025, 6:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

Recursion reports positive Phase 1b/2 data for REC-4881 in FAP: 75% show polyp burden reduction

75% of evaluable patients reduced total polyp burden at 12 weeks; median reduction 43%.
November 5, 2025, 6:59 PM ET leadership materiality 0.80 neutral item 2.02 item 5.02 item 7.01 item 9.01

Recursion appoints Najat Khan as CEO effective Jan 1, 2026; Q3 net loss $162.3M

Najat Khan succeeds Chris Gibson as CEO and President effective Jan 1, 2026; Gibson becomes Chairman.
October 29, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01

Roche exercises option for Recursion's Microglia Map; $30M fee

Roche exercised option for a first-of-its-kind whole genome map of brain immune cells (Microglia Map) from Recursion.
August 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.02 item 8.01 item 9.01

Recursion issues 2.4M contingent shares to Rallybio after GLP tox milestone

Milestone triggered by initiation of GLP toxicology study on August 25, 2025.
August 5, 2025, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 7.01 item 9.01

Recursion Q2 2025: $7M Sanofi milestone; REC-1245 and REC-617 trial updates

Announced $7 million milestone from Sanofi partnership for partnered discovery program.
July 8, 2025, 7:59 PM ET M&A materiality 0.65 positive item 3.02 item 7.01 item 8.01 item 9.01

Recursion acquires full ownership of oral ENPP1 inhibitor program from Rallybio

Buys Rallybio's 50% stake in ENPP1 JV, gaining full rights to REV102 for hypophosphatasia.
June 10, 2025, 7:59 PM ET other material materiality 0.70 neutral item 2.05 item 7.01 item 9.01

Recursion cuts workforce ~20%, extends cash runway to Q4 2027; $11M severance charges

Workforce reduction of ~20%; expects ~$11M in severance and related costs in 2025.
May 5, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

Recursion Q1 net loss widens to $202.5M; Sanofi milestone $7M; pipeline refocused

Q1 net loss $202.5M vs $91.4M YoY; revenue $15M (up from $14M).
February 28, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Recursion reports Q4 net loss $178.9M, FY2024 net loss $463.7M; cash runway into 2027

Cash, cash equivalents and restricted cash $603.0M at Dec 31, 2024 vs $401.4M at Dec 31, 2023; runway extended into 2027.
November 27, 2024, 6:59 PM ET M&A materiality 0.75 neutral item 9.01

Recursion completes Exscientia acquisition; pro forma shows increased net losses

Total purchase price ~$635.9M; transaction closed Nov 20, 2024.
November 20, 2024, 6:59 PM ET M&A materiality 0.85 neutral item 2.01 item 5.02 item 7.01 item 8.01 item 9.01 item 6.01

Recursion completes Exscientia acquisition; issues 102M shares, names new CFO

Acquisition of Exscientia effective Nov 20, 2024 via UK scheme; 0.7729 Recursion shares per Exscientia share; 102,138,419 shares issued.
November 13, 2024, 6:59 PM ET M&A materiality 0.85 positive item 8.01 item 9.01

Recursion & Exscientia shareholders approve combination; close expected Nov 20

Overwhelming shareholder approval from both Recursion (RXRX) and Exscientia (EXAI) for the proposed combination.
November 13, 2024, 6:59 PM ET other material materiality 0.70 positive item 5.07

Recursion shareholders approve stock issuance for Exscientia acquisition

Shareholders voted 99.77% in favor (250.9M votes for) of issuing Class A common stock for the Exscientia acquisition.
November 6, 2024, 6:59 PM ET M&A materiality 0.65 neutral item 1.01 item 8.01 item 9.01

Recursion amends Exscientia acquisition to clarify post-closing board appointments

Amendment lets Exscientia designate one board member (subject to Recursion board approval) effective at closing; a second member if mutually agreed.
November 6, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Recursion Q3 revenue $26.1M, net loss $95.8M; Exscientia merger on track

Revenue surged to $26.1M from $10.5M YoY; net loss $95.8M vs $93.0M; no EPS provided.
October 2, 2024, 7:59 PM ET regulatory materiality 0.65 positive item 7.01 item 9.01

FDA clears IND for Recursion's REC-1245, a first-in-class RBM39 degrader for solid tumors/lymphoma

FDA cleared IND for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.
September 3, 2024, 7:59 PM ET other material materiality 0.75 neutral item 7.01 item 8.01 item 9.01

Recursion reports top-line SYCAMORE data, files Exscientia financials for proposed merger

SYCAMORE Phase 2 trial for REC-994 in symptomatic CCM patients: top-line results announced Sept 3, 2024 (press release as Exhibit 99.2).
August 28, 2024, 7:59 PM ET M&A materiality 0.60 positive item 8.01 item 9.01

Evotec commits ~11% Exscientia shares to Recursion deal; total committed ~53%

Evotec SE, holding ~11% of Exscientia shares, executed irrevocable undertaking on Aug 28 to vote in favor of Recursion acquisition.
August 8, 2024, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 2.02 item 3.02 item 5.02 item 7.01 item 9.01

Recursion acquires Exscientia in stock deal; director Burrell resigns; Q2 results reported

Recursion to acquire Exscientia via UK scheme of arrangement; Exscientia shareholders get 0.7729 Recursion shares per share.
August 6, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01

Recursion announces Roche exercises option for first Neuroscience Phenomap; receives $30M fee

Roche exercised option for first Neuroscience Phenomap under 2021 Collaboration Agreement.
June 27, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

Recursion prices $200M public offering of 30.8M shares at $6.50 per share

Gross proceeds ~$200M before underwriting discounts and estimated offering expenses.
June 24, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Recursion gives guidance on seven clinical readouts within ~18 months and Bayer LOWE partnership

Topline Phase 2 data for REC-994 (CCM) in Sep 2024; prelim Phase 2 data for REC-2282 (NF2) in Q4 2024.
May 24, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 4.01 item 5.02 item 7.01 item 9.01

Recursion appoints Robert Hershberg as new board chair; Martin Chavez to exit at 2024 annual meeting

Martin Chavez not standing for re-election; term ends at 2024 Annual Meeting; no disagreement with company.